ClinicalTrials.gg
Active, not recruitingNCT05889182Step-Up HSUpdated Nov 13, 2026

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

A Phase 3 interventional study of Upadacitinib and Placebo in Hidradenitis Suppurativa, sponsored by AbbVie. Active, not recruiting at 285 sites in 37 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,328
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.

Planned enrollment
2nd of 11
1,328 · median 243
Started
2023
the only one that year
Phase 3
6 of 18
none open now
Registered
15th of 18
by date

Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 6 in phase 3, and was the 15th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hidradenitis Suppurativa by AbbVie, or all of them as a file.
02

Study summary

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed.

Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide.

Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Upadacitinib
  • ABT-494
  • Rinvoq
  • STEP-UP HS
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hidradenitis suppurativa (HS) for at least 6 months prior to Baseline, as determined by the investigator (i.e., through medical history and interview of participant).
  • Documented history of previous use of >= 1 tumor necrosis factor (TNF) inhibitor for HS for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks characterized by inadequate response or for any duration characterized by intolerance as determined by the investigator.
  • Participant must have a total abscess and inflammatory nodule (AN) count of >= 5 at Baseline.
  • HS lesions must be present in at least 2 distinct anatomic areas at Baseline.
  • At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.
  • Draining fistula count of \<= 20 at Baseline.

Exclusion criteria

Exclusion Criteria:

  • History of active skin disease other than HS that could interfere with the assessment of HS, including skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline visit.
  • Treatment with any drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug or be currently enrolled in another interventional clinical study. Investigational drugs are also prohibited during the study.
  • Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 (e.g., rituximab) within 12 months prior to Baseline or until B cell count returns to normal level or pre-treatment level.
  • Use of prescription topical therapies (including topical antibiotics) that can also be used to treat HS within 14 days prior to the Baseline visit.
  • Received any systemic (including oral) antibiotic treatment for HS or any other chronic inflammatory disorder within 14 days prior to the Baseline visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,328 participants (estimated)

Study arms

  • Experimental
    Period 1: Upadacitinib Dose A

    Participants will receive Upadicitinib Dose A once daily for 16 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Period 1: Placebo

    Participants will receive Placebo once daily for 16 weeks.

    Drug: Placebo

  • Experimental
    Period 2: Group 1 - Upadacitinib Dose A

    Participants who were randomized to placebo in Period 1 who did not achieve HiSCR 50 (clinical non-responder, CNR) at Week 16 will receive Upadacitinib Dose A once daily for 20 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Period 2: Group 2 - Placebo

    Participants who were randomized to placebo in Period 1 who achieve HiSCR 50 (clinical responder, CR) at Week 16 will continue to receive placebo once daily for 20 weeks.

    Drug: Placebo

  • Experimental
    Period 2: Group 3 - Upadacitinib Dose A

    Participants who were randomized to upadacitinib Dose A in Period 1 who did not achieve HiSCR 50 (CNR) at Week 16 will continue to receive upadacitinib Dose A once daily for 20 weeks.

    Drug: Upadacitinib

  • Experimental
    Period 2: Group 4 - Upadacitinib Dose A

    Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose A once daily for 20 weeks.

    Drug: Upadacitinib

  • Experimental
    Period 2: Group 5 - Upadacitinib Dose B

    Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose B once daily for 20 weeks.

    Drug: Upadacitinib

  • Experimental
    Period 2: Group 6 - Placebo

    Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive placebo once daily for 20 weeks.

    Drug: Placebo

  • Experimental
    Period 3: Long-Term Extension

    Eligible participants will continue to receive upadacitinib or placebo for 68 weeks. Participants will be followed-up for approximately 30 days.

    Drug: Upadacitinib · Drug: Placebo

Interventions

  • Oral Tablets

    Also known as: ABT-494, RINVOQ

  • DrugPlacebo

    Oral Tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50

    HiSCR 50 is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

    Time frame: Baseline to Week 16

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately Week 108

Secondary outcomes

  1. Change from Baseline in Draining Fistula Count

    Change from baseline in draining fistula count.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75

    HiSCR 75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

    Time frame: Baseline to Week 16

  3. Percentage of Participants Achieving Numeric Rating Scale 30 (NRS30) at Week 4 Among Participants with NRS ≥ 3 at Baseline

    Achievement will be considered at least a 30% reduction and at least 2 units reduction from Baseline in the Participant's Global Assessment (PGA) of HS-related skin pain NRS based on worst skin pain in a 24-hour recall period (maximal daily pain). The PGA Skin Pain is an 11-point numerical rating scale with ratings for the item ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).

    Time frame: Baseline to Week 4

  4. Percentage of Participants Achieving NRS3 at Week 4 Among Participants with NRS ≥ 3 at Baseline

    Achievement will be considered least 3 units reduction from Baseline in the Participant's Global Assessment (PGA) of HS-related skin pain NRS based on worst skin pain in a 24-hour recall period (maximal daily pain). The PGA Skin Pain is an 11-point numerical rating scale with ratings for the item ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).

    Time frame: Baseline to Week 4

  5. Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA)

    The HSSA (24-hour recall) is a 9-item PRO questionnaire developed to assess the primary symptoms of HS in the 7 consecutive days prior to assessments. Each item of the HSSA is scored on an 11-point (0 to 10) NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.

    Time frame: Baseline to Week 16

  6. Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)

    The HSIA is an 18-item PRO questionnaire developed to assess the impact of HS on the daily lives of subjects in the 7 days prior to the assessment. Items 1 - 16 of the HSIA are scored on a 0 to 10 NRS, where 0 represents no impact and 10 represents extreme impact.

    Time frame: Baseline to Week 16

  7. Change from Baseline in Dermatology Life Quality Index (DLQI) for Adult Participants and Adolescent Participants Age ≥16 Years Old and Older

    The DLQI and the CDLQI are both 10-item questionnaires used to assess the impact of hidradenitis suppurativa (HS) disease symptoms and treatment on quality of life that consists of 10 questions scored on a 4-point scale where 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much.

    Time frame: Baseline to Week 16

  8. Occurrence of Hidradenitis Suppurativa (HS) Flare During Period 1

    Defined as at least one occurrence of a ≥ 25% increase in AN count, with a minimum absolute increase of 2 relative to Baseline.

    Time frame: Baseline to Week 16

07

Study locations

285 sites

Showing the first 100 of 285 sites across 37 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Aug 2028, 62 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 62 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2028 → Aug 2028 and completion Sep 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 5, 2023
StartActual
Jun 21, 2023
Primary completionEst.
Aug 2028was Mar 2028
CompletionEst.
Aug 2028was Sep 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
20 sites added, 20 sites removed
Show 20 added (10 United States, 2 Canada, 2 Germany, 1 Argentina, 1 France, 1 Ireland, 1 Japan, 1 Slovakia, 1 United Kingdom)
  • Cahaba Dermatology and Skin Health Center /ID# 254876 · Birmingham, United States
  • Mayo Clinic Hospital Scottsdale /ID# 254388 · Scottsdale, United States
  • Northwest Arkansas Clinical Trials Center /ID# 254311 · Rogers, United States
  • Norcal Clinical Research /ID# 274219 · Rocklin, United States
  • Life Clinical Trials - Coral Springs /ID# 258613 · Coral Springs, United States
  • Illinois Dermatology Institute - Chicago Loop Office /ID# 254372 · Chicago, United States
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 254503 · Chicago, United States
  • Equity Medical /ID# 271140 · Bowling Green, United States
  • OnSite Clinical Solutions - North Community House Road - Charlotte /ID# 254854 · Charlotte, United States
  • Dermatologists of Southwest Ohio /ID# 254297 · Mason, United States
  • Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 255474 · Buenos Aires, Argentina
  • Lynderm Research /ID# 254713 · Markham, Canada
  • Centre Hospitalier Universitaire (CHU) Sainte-Justine /ID# 254118 · Montreal, Canada
  • Chu De Nice-Hopital Larchet II /ID# 253504 · Nice, France
  • Klinikum rechts der Isar Technische Universitat Munchen /ID# 254195 · Munich, Germany
  • Universitaetsklinikum Der Ruhr-Universitaet Bochum /ID# 253690 · Bochum, Germany
  • St. Vincent's University Hospital /ID# 253971 · Dublin, Ireland
  • Nihon University Itabashi Hospital /ID# 254637 · tabashi City, Japan
  • Fakultna nemocnica Trnava /ID# 254137 · Trnava, Slovakia
  • West Middlesex University Hospital /ID# 254190 · Isleworth, United Kingdom
Show 20 removed
  • Cahaba Dermatology & Skin Health Center /ID# 254876 · Birmingham, United States
  • Mayo Clinic - Scottsdale /ID# 254388 · Scottsdale, United States
  • NW Arkansas Clinical Trials Center /ID# 254311 · Rogers, United States
  • NorCal Clinical Research /ID# 274219 · Rocklin, United States
  • Life Clinical Trials - N State Rd - Margate /ID# 258613 · Margate, United States
  • DeNova Research /ID# 254372 · Chicago, United States
  • Northwestern University Feinberg School of Medicine /ID# 254503 · Chicago, United States
  • Equity Medical, LLC /ID# 271140 · Bowling Green, United States
  • Onsite Clinical Solutions - Community House Rd - Charlotte /ID# 254854 · Charlotte, United States
  • Dermatologists of Southwest Ohio, Inc /ID# 254297 · Mason, United States
  • Ciprec (Centro De Investigacion Y Prevencion Cardiovascular) - Barrio Norte /ID# 255474 · Buenos Aires, Argentina
  • Lynderm Research Inc /ID# 254713 · Markham, Canada
  • CHU Sainte-Justine /ID# 254118 · Montreal, Canada
  • Chu de Nice-Hopital Larchet Ii /Id# 253504 · Nice, France
  • Klinikum Ruhr Univ Bochum /ID# 253690 · Bochum, Germany
  • Klinik am Biederstein /ID# 254195 · Munich, Germany
  • University College Dublin /ID# 253971 · Dublin, Ireland
  • Nihon University Itabashi Hospital /ID# 254637 · Itabashi-ku, Japan
  • Fakultna nemocnica Trnava /ID# 254137 · Trnava, Slovakia
  • Chelsea and Westminster Hospital /ID# 254190 · London, United Kingdom
Nov 13, 2026
Primary completion
Mar 2028→Aug 2028
Nov 13, 2026
Study completion
Sep 2028→Aug 2028
Nov 13, 2026
Secondary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedPercentage of Participants Achieving NRS3 at Week 4 Among Participants with NRS ≥ 3 at BaselineTime frame: Baseline to Week 4
  • RemovedChange from Baseline in Hidradenitis Suppurativa (HS)-Related Odor, Based on Hidradenitis Suppurativa Symptom Assessment (HSSA) Question 8Time frame: Baseline to Week 16
  • RemovedChange from Baseline in the Patient's Global Assessment of Hidradenitis Suppurativa (HS)-Related Skin Pain NRSTime frame: Baseline to Week 8
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    20 sites added, 20 sites removed
    Show 20 added (10 United States, 2 Canada, 2 Germany, 1 Argentina, 1 France, 1 Ireland, 1 Japan, 1 Slovakia, 1 United Kingdom)
    • Cahaba Dermatology and Skin Health Center /ID# 254876 · Birmingham, United States
    • Mayo Clinic Hospital Scottsdale /ID# 254388 · Scottsdale, United States
    • Northwest Arkansas Clinical Trials Center /ID# 254311 · Rogers, United States
    • Norcal Clinical Research /ID# 274219 · Rocklin, United States
    • Life Clinical Trials - Coral Springs /ID# 258613 · Coral Springs, United States
    • Illinois Dermatology Institute - Chicago Loop Office /ID# 254372 · Chicago, United States
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 254503 · Chicago, United States
    • Equity Medical /ID# 271140 · Bowling Green, United States
    • OnSite Clinical Solutions - North Community House Road - Charlotte /ID# 254854 · Charlotte, United States
    • Dermatologists of Southwest Ohio /ID# 254297 · Mason, United States
    • Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 255474 · Buenos Aires, Argentina
    • Lynderm Research /ID# 254713 · Markham, Canada
    • Centre Hospitalier Universitaire (CHU) Sainte-Justine /ID# 254118 · Montreal, Canada
    • Chu De Nice-Hopital Larchet II /ID# 253504 · Nice, France
    • Klinikum rechts der Isar Technische Universitat Munchen /ID# 254195 · Munich, Germany
    • Universitaetsklinikum Der Ruhr-Universitaet Bochum /ID# 253690 · Bochum, Germany
    • St. Vincent's University Hospital /ID# 253971 · Dublin, Ireland
    • Nihon University Itabashi Hospital /ID# 254637 · tabashi City, Japan
    • Fakultna nemocnica Trnava /ID# 254137 · Trnava, Slovakia
    • West Middlesex University Hospital /ID# 254190 · Isleworth, United Kingdom
    Show 20 removed
    • Cahaba Dermatology & Skin Health Center /ID# 254876 · Birmingham, United States
    • Mayo Clinic - Scottsdale /ID# 254388 · Scottsdale, United States
    • NW Arkansas Clinical Trials Center /ID# 254311 · Rogers, United States
    • NorCal Clinical Research /ID# 274219 · Rocklin, United States
    • Life Clinical Trials - N State Rd - Margate /ID# 258613 · Margate, United States
    • DeNova Research /ID# 254372 · Chicago, United States
    • Northwestern University Feinberg School of Medicine /ID# 254503 · Chicago, United States
    • Equity Medical, LLC /ID# 271140 · Bowling Green, United States
    • Onsite Clinical Solutions - Community House Rd - Charlotte /ID# 254854 · Charlotte, United States
    • Dermatologists of Southwest Ohio, Inc /ID# 254297 · Mason, United States
    • Ciprec (Centro De Investigacion Y Prevencion Cardiovascular) - Barrio Norte /ID# 255474 · Buenos Aires, Argentina
    • Lynderm Research Inc /ID# 254713 · Markham, Canada
    • CHU Sainte-Justine /ID# 254118 · Montreal, Canada
    • Chu de Nice-Hopital Larchet Ii /Id# 253504 · Nice, France
    • Klinikum Ruhr Univ Bochum /ID# 253690 · Bochum, Germany
    • Klinik am Biederstein /ID# 254195 · Munich, Germany
    • University College Dublin /ID# 253971 · Dublin, Ireland
    • Nihon University Itabashi Hospital /ID# 254637 · Itabashi-ku, Japan
    • Fakultna nemocnica Trnava /ID# 254137 · Trnava, Slovakia
    • Chelsea and Westminster Hospital /ID# 254190 · London, United Kingdom
    Primary completion Mar 2028→Aug 2028
    Study completion Sep 2028→Aug 2028
    Secondary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedPercentage of Participants Achieving NRS3 at Week 4 Among Participants with NRS ≥ 3 at BaselineTime frame: Baseline to Week 4
    • RemovedChange from Baseline in Hidradenitis Suppurativa (HS)-Related Odor, Based on Hidradenitis Suppurativa Symptom Assessment (HSSA) Question 8Time frame: Baseline to Week 16
    • RemovedChange from Baseline in the Patient's Global Assessment of Hidradenitis Suppurativa (HS)-Related Skin Pain NRSTime frame: Baseline to Week 8
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05889182
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Jun 21, 2023
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion